Loading...
XNAS
ILMN
Market cap19bUSD
Dec 05, Last price  
128.96USD
1D
0.73%
1Q
30.35%
Jan 2017
0.72%
IPO
636.91%
Name

Illumina Inc

Chart & Performance

D1W1MN
XNAS:ILMN chart
P/E
P/S
4.51
EPS
Div Yield, %
Shrs. gr., 5y
1.31%
Rev. gr., 5y
4.29%
Revenues
4.37b
-2.93%
73,501,000184,586,000366,799,000573,225,000666,324,000902,741,0001,055,535,0001,148,516,0001,421,178,0001,861,358,0002,219,762,0002,398,373,0002,752,000,0003,333,000,0003,543,000,0003,239,000,0004,526,000,0004,584,000,0004,504,000,0004,372,000,000
Net income
-1.22b
L+5.34%
-20,874,00039,968,000-278,359,00050,477,00072,281,000124,891,00086,628,000151,254,000125,308,000353,351,000461,559,000462,649,000726,000,000826,000,0001,002,000,000656,000,000762,000,000-4,404,000,000-1,161,000,000-1,223,000,000
CFO
837m
+75.10%
-9,008,00039,000,00056,294,00087,882,000174,496,000272,573,000358,140,000291,873,000386,421,000501,271,000659,596,000687,238,000875,000,0001,142,000,0001,051,000,0001,080,000,000545,000,000392,000,000478,000,000837,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
IPO date
Jun 28, 2000
Employees
11,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122023‑002022‑002021‑002019‑122018‑122017‑122017‑002016‑00
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT